P692: THE KEAP1-NRF2 REDOX PATHWAY IS OF CENTRAL IMPORTANCE DURING 5-AZACYTIDINE THERAPY AND THE DEVELOPMENT OF RESISTANCE VIA A SPECIFIC SET OF PROTEIN OXIDATIVE MODIFICATIONS by Kristýna Pimková, Lubomír Minařík, Michaela Myšáková, Juraj Kokavec, Tomáš Stopka

Get full text

Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML by Petra Bašová, Lubomír Minařík, Lubomír Minařík, Silvia Carina Magalhaes-Novais, Jana Balounová, Zuzana Zemanová, Tatiana Aghová, Martin Špaček, Anna Jonášová, Kristýna Gloc Pimková, Jan Procházka, Radislav Sedláček, Tomáš Stopka, Tomáš Stopka

Get full text

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial by Tomáš Stopka, Lubomír Minařík, Nina Dusilková, Michal Pešta, Vojtěch Kulvait, Martin Špaček, Zuzana Zemanová, Marta Kalousová, Anna Jonášová

Get full text

Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of com... by Anna Jonasova, Slavka Sotakova, Petra Belohlavkova, Lubomir Minarik, Tomas Stopka, Tomas Stopka, Jan Jakub Jonas, Tatiana Aghova, Zuzana Zemanova

Get full text

Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways by Lubomír Minařík, Kristýna Pimková, Juraj Kokavec, Adéla Schaffartziková, Fréderic Vellieux, Vojtěch Kulvait, Lenka Daumová, Nina Dusilková, Anna Jonášová, Karina Savvulidi Vargová, Petra Králová Viziová, Radislav Sedláček, Zuzana Zemanová, Tomáš Stopka

Get full text